SNORD103B: A Potential Drug Target and Biomarker (G692235)

Target Name: SNORD103B

NCBI ID: G692235

SNORD103B

Other Name(s): Small nucleolar RNA, C/D box 103B | small nucleolar RNA, C/D box 103B | U103B

SNORD103B: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the most well-studied classes of snRNAs is the C/D box snRNAs, which contain a conserved core structure composed of a characteristic C/D box and a variable extension. C/D box snRNAs are widely expressed in various tissues and are involved in the regulation of various cellular processes, including DNA replication, gene expression, and chromatin remodeling.

One of the C/D box snRNAs that has generated significant interest in recent years is SNORD103B. This RNA molecule has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will provide an overview of SNORD103B, including its structure, function, and potential as a drug target and biomarker.

Structure and Function

SNORD103B is a 24.1-kcalium (kcal) RNA molecule with a 191-amino acid (aa) length. It has a characteristic C/D box structure, with a conserved core of 12 amino acids and a variable extension that includes a poly(A ) tail and a unique GCAATTTG Repeat. The C/D box region of SNORD103B is composed of a specificity domain, which is responsible for binding to specific DNA sequences, and a T-loop region that is involved in the formation of a double helix.

SNORD103B is expressed in various tissues and is involved in the regulation of gene expression. One of the most well-studied functions of SNORD103B is its role in the regulation of DNA replication. In S. cerevisiae, SNORD103B has been shown to play a role in the regulation of DNA replication by binding to the double helix at GAAATTTG Repeat, which is located close to the start of the replication frame. By binding to this specific DNA sequence, SNORD103B can prevent the completion of the double helix and disrupt the replication process.

In addition to its role in DNA replication, SNORD103B has also been shown to play a critical role in the regulation of gene expression. In various cell types, SNORD103B has been shown to interact with specific RNA binding proteins, including the RNA polymerase II (RNA -P) complex. This interaction between SNORD103B and RNA-P allows SNORD103B to function as a negative regulator of RNA-P, which is responsible for the translation of mRNAs from the RNA world to the protein world.

Potential as a Drug Target

The potential of SNORD103B as a drug target and biomarker is due to its unique structure and function. One of the main advantages of SNORD103B is its small size, which allows for efficient delivery to target cells and for efficient modulation of its activity. In addition, the conserved nature of the C/D box region and the unique GCAATTTG Repeat make SNORD103B a promising candidate for small molecule inhibitors, which can be used to stabilize or inhibit its activity.

SNORD103B has also been shown to interact with specific protein targets, including the protein kinase Ago1 (KYA). In various cell types, SNORD103B has been shown to physically interact with KYA 鈥嬧?媋nd to play a role in the regulation of KYA-mediated signaling pathways. This interaction between SNORD103B and KYA suggests that SNORD103B may be a useful drug target for the treatment of diseases that are characterized by the over-activation of

Protein Name: Small Nucleolar RNA, C/D Box 103B

The "SNORD103B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD103B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets